IRVINE, Calif., Sept. 07, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE:VSI). Investors who purchased or otherwise acquired shares between March 1, 2017 and August 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 27, 2017 lead plaintiff motion deadline.
If you purchased Vitamin Shoppe shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Vitamin Shoppe made false and/or misleading statements, and/or failed to disclose: that the Company’s retail segment was continuing to dramatically decline; that its ongoing “reinvention plan” had been unsuccessful and brought more than $168 million in goodwill impairment, and it was not properly recognizing that impairment charge; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On May 10, 2017, Vitamin Shoppe released first quarter 2017 financial results that were lower than market expectations and slashed its fiscal 2017 guidance by 45%, yet claimed the “reinvention plan” was still succeeding. Following this news, the Company’s stock price fell dramatically. On August 9, 2017, the Company announced that it was taking a $168.1 million impairment charge on the goodwill being carried on its books associated with its retail segment, and that it would report a loss per share of $6.73. Also, citing “the potential increase in variability of the Company’s results due to the number of initiatives being launched in the back half of the year,” Vitamin Shoppe dropped its fiscal 2017 earnings per share guidance altogether. When this news was announced to the public, the Company’s shares declined in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anta Sports Expands Global Footprint With Strategic Puma Stake
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Samsung Electronics Shares Jump on HBM4 Mass Production Report
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 



